» Articles » PMID: 16843750

Chemotherapy-induced Sclerosing Cholangitis

Overview
Journal Clin Radiol
Specialty Radiology
Date 2006 Jul 18
PMID 16843750
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To review the computed tomography (CT), magnetic resonance imaging (MRI) and cholangiographic findings of chemotherapy-induced sclerosing cholangitis (CISC).

Methods: Between January 1995 and December 2004, 11 patients in the endoscopic retrograde cholangiography database were identified with CISC. Twelve CT, four MRI, 69 endoscopic and nine antegrade cholangiographic studies in these patients were reviewed. Serial change in appearance and response to endoscopic treatment were recorded.

Results: CISC showed segmental irregular biliary dilatation with strictures of proximal extrahepatic bile ducts. The distal 5cm of common bile duct was not affected in any patient. CT and MRI findings included altered vascular perfusion of one or more liver segments, liver metastases or peritoneal carcinomatosis. Biliary strictures needed repeated stenting in 10 patients (mean: every 4.7 months). Cirrhosis (n=1) or confluent fibrosis (n=0) were uncommon findings.

Conclusion: CISC shares similar cholangiographic appearances to primary sclerosing cholangitis (PSC). Unlike PSC, biliary disease primarily involved ducts at the hepatic porta rather than intrahepatic ducts. Multiphasic contrast-enhanced CT or MRI may show evidence of perfusion abnormalities, cavitary liver lesions, or metastatic disease.

Citing Articles

Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications.

Zhao J, Yue P, Mi N, Li M, Fu W, Zhang X Med Rev (2021). 2024; 4(4):326-365.

PMID: 39135601 PMC: 11317084. DOI: 10.1515/mr-2024-0029.


Secondary sclerosing cholangitis and IgG4-sclerosing cholangitis - A review of cholangiographic and ultrasound imaging.

Moller K, Braden B, Culver E, Jenssen C, Safai Zadeh E, Alhyari A Endosc Ultrasound. 2023; 12(2):181-199.

PMID: 36588352 PMC: 10237613. DOI: 10.4103/EUS-D-22-00208.


Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report.

Tanaka T, Sakai A, Tsujimae M, Yamada Y, Kobayashi T, Masuda A World J Gastroenterol. 2022; 28(28):3732-3738.

PMID: 36161046 PMC: 9372812. DOI: 10.3748/wjg.v28.i28.3732.


Ceftriaxone-induced hepatotoxicity in patients with common medical infections in Qatar: A retrospective study.

Barman M, Al Hariri B, Rahman Mustafa A, Ambra N, Amjed I, Alharafsheh A Qatar Med J. 2022; 2022(3):27.

PMID: 35864919 PMC: 9272765. DOI: 10.5339/qmj.2022.27.


Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis.

Calistri L, Rastrelli V, Nardi C, Maraghelli D, Vidali S, Pietragalla M World J Gastroenterol. 2022; 27(46):7866-7893.

PMID: 35046618 PMC: 8678821. DOI: 10.3748/wjg.v27.i46.7866.